365 related articles for article (PubMed ID: 29759386)
1. Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy.
Mazur M; Wang F; Hodge DO; Siontis BL; Beinborn DS; Villarraga HR; Lerman A; Friedman PA; Herrmann J
JACC Clin Electrophysiol; 2017 Feb; 3(2):139-150. PubMed ID: 29759386
[TBL] [Abstract][Full Text] [Related]
2. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
[TBL] [Abstract][Full Text] [Related]
3. Significant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac defibrillator.
Noda T; Kurita T; Nitta T; Chiba Y; Furushima H; Matsumoto N; Toyoshima T; Shimizu A; Mitamura H; Okumura K; Ohe T; Aizawa Y
Int J Cardiol; 2018 Mar; 255():85-91. PubMed ID: 29425569
[TBL] [Abstract][Full Text] [Related]
4. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
[TBL] [Abstract][Full Text] [Related]
6. Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators.
Corden B; Jarman J; Whiffin N; Tayal U; Buchan R; Sehmi J; Harper A; Midwinter W; Lascelles K; Markides V; Mason M; Baksi J; Pantazis A; Pennell DJ; Barton PJ; Prasad SK; Wong T; Cook SA; Ware JS
JAMA Netw Open; 2019 Jun; 2(6):e196520. PubMed ID: 31251381
[TBL] [Abstract][Full Text] [Related]
7. Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy.
Patel D; Kumar A; Moennich LA; Trulock K; Nemer DM; Donnellan E; Il'Giovine ZJ; Martyn T; Callahan TD; Hussein AA; Tarakji KG; Kanj M; Cantillon DJ; Baranowski B; Starling RC; Tang WHW; Wazni OM; Varma N; Wilkoff BL; Rickard J
Heart; 2022 Feb; 108(4):274-278. PubMed ID: 34489312
[TBL] [Abstract][Full Text] [Related]
8. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy.
Oliveira GH; Qattan MY; Al-Kindi S; Park SJ
Circ Heart Fail; 2014 Nov; 7(6):1050-8. PubMed ID: 25415958
[No Abstract] [Full Text] [Related]
9. Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: A report from the Pediatric Heart Transplant Study (PHTS) group.
Bock MJ; Pahl E; Rusconi PG; Boyle GJ; Parent JJ; Twist CJ; Kirklin JK; Pruitt E; Bernstein D
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28378408
[TBL] [Abstract][Full Text] [Related]
10. Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate.
Barra S; Boveda S; Providência R; Sadoul N; Duehmke R; Reitan C; Borgquist R; Narayanan K; Hidden-Lucet F; Klug D; Defaye P; Gras D; Anselme F; Leclercq C; Hermida JS; Deharo JC; Looi KL; Chow AW; Virdee M; Fynn S; Le Heuzey JY; Marijon E; Agarwal S;
J Am Coll Cardiol; 2017 Apr; 69(13):1669-1678. PubMed ID: 28359511
[TBL] [Abstract][Full Text] [Related]
11. Sex-Based Differences in Selected Cardiac Implantable Electronic Device Use: A 10-Year Statewide Patient Cohort.
De Silva K; Nassar N; Badgery-Parker T; Kumar S; Taylor L; Kovoor P; Zaman S; Wilson A; Chow CK
J Am Heart Assoc; 2022 Aug; 11(16):e025428. PubMed ID: 35943057
[TBL] [Abstract][Full Text] [Related]
12. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
[TBL] [Abstract][Full Text] [Related]
13. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
[TBL] [Abstract][Full Text] [Related]
15. Impact of Improved Left Ventricular Systolic Function on the Recurrence of Ventricular Arrhythmia in Heart Failure Patients With an Implantable Cardioverter-Defibrillator.
Kim M; Kim J; Lee JH; Hwang YM; Kim MS; Nam GB; Choi KJ; Kim JJ; Kim YH
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1191-1198. PubMed ID: 27334231
[TBL] [Abstract][Full Text] [Related]
16. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
[TBL] [Abstract][Full Text] [Related]
17. [Predictive parameters of occurrence of adequate interventions in patients with implanted cardioverter-defibrillators with or without resynchronisation therapy in primary prevention of sudden cardiac death in dilated cardiomyopathy].
Lelakowski J; Rydlewska A; Lelakowska M; Pudło J; Piekarz J
Pol Merkur Lekarski; 2017 Feb; 42(248):65-70. PubMed ID: 28258679
[TBL] [Abstract][Full Text] [Related]
18. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
[TBL] [Abstract][Full Text] [Related]
20. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
